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Background: The two-stage tissue expander/implant (TE/I) reconstruction is currently the gold standard method of
implant-based immediate breast reconstruction in North America. Recently, however, there have been numerous
case series describing the use of one-stage direct to implant reconstruction with the aid of acellular dermal matrix
(ADM). In order to rigorously investigate the novel application of ADM in one-stage implant reconstruction, we are
currently conducting a multicentre randomized controlled trial (RCT) designed to evaluate the impact on patient
satisfaction and quality of life (QOL) compared to the two-stage TE/I technique.
Methods/designs: The MCCAT study is a multicenter Canadian ADM trial designed as a two-arm parallel
superiority trial that will compare ADM-facilitated one-stage implant reconstruction compared to two-stage TE/I
reconstruction following skin-sparing mastectomy (SSM) or nipple-sparing mastectomy (NSM) at 2 weeks, 6 months,
and 12 months. The source population will be members of the mastectomy cohort with stage T0 to TII disease,
proficient in English, over the age of 18 years, and planning to undergo SSM or NSM with immediate implant
breast reconstruction. Stratified randomization will maintain a balanced distribution of important prognostic factors
(study site and unilateral versus bilateral procedures). The primary outcome is patient satisfaction and QOL as
measured by the validated and procedure-specific BREAST-Q. Secondary outcomes include short- and long-term
complications, long-term aesthetic outcomes using five standardized photographs graded by three independent
blinded observers, and a cost effectiveness analysis.
Discussion: There is tremendous interest in using ADM in implant breast reconstruction, particularly in the setting
of one-stage direct to implant reconstruction where it was previously not possible without the intermediary use of
a temporary tissue expander (TE). This unique advantage has led many patients and surgeons alike to believe that
one-stage ADM-assisted implant reconstruction should be the procedure of choice and should be offered to
patients as the first-line treatment. We argue that it is crucial that this technique be scientifically evaluated in terms
of patient selection, surgical technique, complications, aesthetic outcomes, cost-effectiveness, and most importantly
patient-reported outcomes before it is promoted as the new gold standard in implant-based breast reconstruction.
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Mastectomy remains a common form of treatment for
breast cancer [1,2]. In addition, there has been a ‘rising
tide’ in mastectomy utilization that can be attributed
to more skin-sparing mastectomies (SSMs) performed
concurrently with immediate breast reconstruction. This
rise may be attributed to better identification of women
at high risk for breast cancer with genetic testing, more
refined methods of imaging, and a clearer picture of the
late adverse effects of breast irradiation [1-4]. Immediate
breast reconstruction has proven to be a safe and benefi-
cial treatment for women diagnosed with early-stage
breast cancer, and offers the benefits of improved body
image, health-related quality of life (HRQOL), and pa-
tient satisfaction [5-12]. For women who have the option
of undergoing breast conserving therapy or mastectomy,
the selection of SSM with immediate reconstruction is
preferred by those who want to avoid radiation and local
recurrence, but do not wish to live with a mastectomy
defect [13].
In 2007, an estimated 57,000 breast reconstructions
were performed to restore mastectomy defects, and ofFigure 1 Schematic drawing of the tissue expansion process. The loca
and is relatively deflated at the initial time of placement, and then gradualthose the majority of cases (34,017) were comprised of
the two-stage, tissue expander/implant (TE/I) technique
in the USA [14]. The two-stage TE/I reconstruction be-
came the gold standard in implant-based immediate
breast reconstruction due to the high complication rates
(25% overall explantation rate) associated with the his-
torical, non-ADM assisted method of one-stage implant
reconstruction, which placed the full weight of the im-
plant on the vulnerable inferior mastectomy flap [15]. In
the first stage immediately following mastectomy, a
tissue expander (TE) is temporarily placed under a
complete musculofascial cover made up of pectoralis
muscle and rectus fascia [16]. Because the musculofas-
cial cover is non-distensible and excessive pressure on
the vulnerable mastectomy flap should be avoided, a
partially filled temporary TE is placed immediately fol-
lowing mastectomy. Postoperatively, serial expansion is
performed weekly in the clinic and exchange of the tem-
porary TE for a permanent implant occurs at a subse-
quent operation (Figure 1).
To address the inconvenience associated with the two
surgeries in the TE/I method, while avoiding the hightion of the tissue expander (TE) is deep to the pectoralis major muscle
ly inflated following surgery.
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stage technique, a number of newer one-stage implant
reconstruction methods have been described [17,18].
One useful technique that can allow the breast mound
to be created in a single stage using a permanent full-
sized breast implant is with the use of ADM [19-21].
ADM is an immunologically inert dermal material de-
rived from cadaveric human skin tissue that evades host
rejection and is safe for use in the human body. Immedi-
ately following mastectomy, ADM is used to extend the
musculofascial cover and in turn creates a large enough
space to accommodate a fully inflated implant. By acting
as an ‘internal hammock’ to support the implant, itA
B
C
Figure 2 Preoperative, intraoperative, and postoperative photos of th
reconstruction following left skin-sparing mastectomy (SSM). (A) Preo
reconstruction. (B) Intraoperative view of ADM acting as an ‘internal hamm
views, following left SSM, one-stage ADM reconstruction and nipple areola
skin-sparing mastectomy.minimizes the tension that is exerted on the vulnerable
mastectomy flap (Figure 2).
Lastly, revascularization from the surrounding tissues
and the ability of ADM to be incorporated into the host
tissues prevent extrusion of the implant [19-21]. It has
been recently described in numerous case reports that
ADM can successfully allow one-stage implant recon-
struction to take place without the use of TEs [20-25].
Salzberg et al. reported the largest series of immediate
one-stage breast reconstruction using ADM (AlloDerm,
LifeCell, Branchburg, NJ, USA) in 260 patients (466
breasts) over an 8-year period [23]. After a mean follow-
up of 29 months, the overall complication rate was 3.9%,e one-stage acellular dermal matrix (ADM)-assisted implant
perative anterior and oblique views, prior to left mastectomy and
ock’ and insertion of a full-sized permanent implant. (C) Postoperative
r complex reconstruction. ADM, acellular dermal matrix; SSM,
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two-stage TE/I reconstructions [26,27]. On the other
hand, however, some reports have suggested that ADM
is associated with higher rates of infection and seroma
formation [24,25], and there is a paucity of research on
its long-term aesthetic outcomes.
In order to rigorously investigate the novel application
of ADM in one-stage implant reconstruction, we are
currently conducting a multicentre randomized con-
trolled trial (RCT) designed to evaluate the impact on
patient satisfaction and quality of life (QOL) compared
to the two-stage TE/I technique, the gold standard in
implant-based breast reconstruction. We hypothesize
that the ability to convert a conventional two-stage
procedure to only one step would improve patient satis-
faction, decrease the morbidity associated with tissue
expansion and two surgeries, and justify the cost of this
biomaterial incurred by the patient, hospital, or health-
care system.
Primary aim of study
1) Compare the mean change in the patient satisfaction
and QOL scores between one-stage ADM-assisted
and two-stage TE/I reconstruction without ADM at
12 months following reconstruction using the
validated BREAST-Q reconstruction module [28].
Secondary aims of study
1) Compare the change in the BREAST-Q global score
over time (2 weeks, 6 months, 12 months) following
reconstruction between the two implant
reconstruction methods.
2) Compare the short- and long-term operative
complication rates.
3) Compare overall aesthetic outcomes using five
standardized photographs graded by three
independent blinded observers using the three-point,
five-item, Lowery breast aesthetic score at 1-year
[29,30].
4) Perform a cost-effectiveness analysis of the two
different methods of implant reconstruction using
person-level cost and effect data.
Methods/design
The MCCAT study is a multicentre randomized controlled
two-arm parallel superiority surgical trial that will compare
ADM-facilitated one-stage implant reconstruction com-
pared to two-stage TE/I reconstruction following SSM or
nipple-sparing mastectomy (NSM) at 2 weeks, 6 months,
and 12 months. Stratified randomization will maintain a
balanced distribution of important prognostic factors across
interventions. Stratification variables will include study site(three strata: Toronto hospitals, ON, Canada; Vancouver
General Hospital, Vancouver, BC, Canada; Tom Baker
Cancer Centre, Calgary, AB, Canada) and laterality of sur-
gery (two strata: unilateral versus bilateral) (Figure 3). This
study was approved by the research ethics board of each in-
stitution, including: Toronto hospitals, University Health
Network Research Ethics Board (ethics ID 09-0267-A),
Women’s College Hospital Research Ethics Board (ethics
ID 2009-0018-B); Vancouver General Hospital, University
of British Columbia Clinical Research Ethics Board (ethics
ID H09-01898); and Tom Baker Cancer Centre, University
of Calgary Conjoint Health Research Ethics Board (ethics
ID E-24812). The MCCAT is an investigator-initiated trial,
sponsored by the institution of the coordinating site
(University Health Network).Participants
The source population will be women planning to
undergo risk-reducing mastectomy for BRCA gene posi-
tivity or therapeutic mastectomy for stage T0 to TII
breast cancer with implant-based immediate breast re-
construction at one of the four study sites. Participant
eligibility will first be determined by the investigating
surgeon at the preoperative consultation. Patients will be
excluded if they have a documented psychiatric history
except depression and anxiety, prior history of breast ir-
radiation or anticipated to need postoperative irradi-
ation, or are active smokers, body mass index (BMI)
greater than 30, or greater than D cup breast size or
grade III breast ptosis.Recruitment and enrollment
New patients considering implant-based immediate breast
reconstruction will be approached for the study during
the initial surgical consultation by the investigating sur-
geon. Furthermore, information regarding the trial is avail-
able online through a trial-specific website, since many
patients choose to educate themselves on their options
prior to initial consultation with the plastic surgeon. Dur-
ing the consultation, the investigating surgeon will first
determine if the patient is eligible to join the trial. If eligi-
bility has been confirmed, the surgeon will explain the
trial and the two surgical procedures under investigation,
including the benefits, risks, and complications of each
option. If the patient is interested in the trial, then the
study coordinator will meet with the patient and provide a
detailed explanation of all aspects of the research study.
Realistic photos of the results of both procedures will be
presented to the patients, as well as examples of the im-
plants, ADM, and TEs. Additionally, if desired, the patient
may be referred to speak with patient volunteers who have
previously undergone the same procedures. After ad-
equate consideration of their options, if the patient agrees
Figure 3 Study design flow chart.
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the informed consent process.
Randomization allocation and blinding
Once informed consent and baseline questionnaires have
been obtained, the study coordinator will obtain the pa-
tient’s randomization arm from opaque, sealed envelopes in
sequence to determine the participant’s randomized treat-
ment allocation. Blocked randomization will be incorpo-
rated into each of the six individual strata (site: three strata;
breast laterality: two strata) in fixed blocks of eight. The
randomization allocation list will be developed by a statisti-
cian using PROC PLAN in SAS (SAS Institute Inc, Cary,
NC, USA). Stratified randomization will maintain a bal-
anced distribution of important prognostic factors acrossinterventions and control for: 1) confounding related to
trial site; and 2) possible unequal proportions of unilateral
versus bilateral procedures. Due to the non-pharmacologic
nature of the intervention, it is not possible to use a placebo
and patients will be informed of their assigned treatment
weeks prior to their scheduled surgery. In addition, the
plastic surgeon performing the procedure will not be
blinded. To reduce the impact of participant ascertainment
bias, study participants will be told that the aim of the study
is to compare different methods of breast reconstruction
without identifying the experimental intervention.
Surgical interventions
In both procedures, the SSM or NSM will be performed
using incisions designed by the plastic surgeon. In most
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lar complex for the skin-sparing approach, and either a
periareolar or inframammary fold incision will be used
for the nipple-sparing approach. Following completion
of the mastectomy, the plastic surgeon will first create
the implant/TE pocket by elevating the pectoralis major
muscle to the preoperatively marked footprint of the
breast pocket. In the experimental group, the ADM will
be used to create the inferolateral aspect of the pocket.
An anatomic cohesive silicone gel (Style 410, Allergan,
Santa Barbara, CA, USA, or Mentor CPG 323, Santa
Barbara, CA, USA) will be placed in the pocket and
closure of the pocket will use an absorbable suture. In
Group B, the control group, in addition to elevating the
pectoralis major muscle, serratus anterior muscle/fascia
laterally and rectus fascia inferiorly, a partially saline
filled anatomic-shaped TE (Allergan) will be placed
beneath the musculofascial pocket and closed using an
absorbable suture. In both procedures, one drain per
breast will be placed deep to the mastectomy skin flap
along the inframammary recess, and an additional drain
per breast will be placed deep to the ADM in the
experimental arm. All patients will receive standard peri-
operative antibiotics. All participating surgeons are staff
surgeons who have experience of both the one-stage and
two-stage procedures, and will perform the assigned
surgery that their patient is randomized to receive. Pa-
tients will be informed prior to surgery that there is a
risk that the one-stage procedure will be converted to a
two-stage procedure (insertion of TE with ADM) if the
mastectomy flap is deemed too thin to support a full-
sized permanent implant intraoperatively.
Interventional agent
ADM (AlloDerm) derived from cadaveric human skin
tissue is supplied by American Association of Tissue
Banks (AATB)-compliant tissue bank, and adheres to
the standards of the AATB and the Food and Drug
Administration’s guidelines. AlloDerm is a human-
derived ADM approved by Health Canada. The authors
have no conflicts of interest with Allergan or LifeCell.
For postoperative treatment in the control group, tissue
expansion will take place on a weekly or biweekly basis
until the TE is filled to the patient’s desired volume or
matches the patient’s contralateral side. All patients in
the control arm will undergo a second exchange proced-
ure, at which time the TE is removed and a permanent
implant is placed using an anatomic cohesive silicone gel
implant at 3 (±3) months.
Primary outcomes
To compare the change in patient satisfaction and QOL
between the two surgical interventions from baseline to
12 months following completion of reconstruction, wewill use the breast reconstruction module of the BREAST-
Q. A patient-reported outcome was selected as the primary
outcome measure as the main goal of breast reconstruction
surgery is to improve patient QOL [28,31-34]. The 12-
month time-point was selected because there is evidence
that QOL evolves dynamically in the first year following
breast cancer surgery and plateaus at 1-year [35,36]. The
BREAST-Q reconstruction module is a patient-reported
outcome measure that was developed to assess HRQOL
and patient satisfaction following breast reconstruction
[28,31-34]. It contains six subscales that measure well-
being and satisfaction before and after reconstruction. A
global score that is a summation of satisfaction and QOL
can be transformed on a scale from 0 to 100 using the
RUMM software (RUMM Laboratory, Perth, Australia).
The measure has excellent reliability, with high internal
consistency (Cronbach’s alpha from 0.88 to 0.96) and test-
retest reliability (intraclass correlation coefficient (ICC) 0.85
to 0.98) for the BREAST-Q subscales [28].
Secondary outcomes
Satisfaction and QOL changes over time will be mea-
sured at discrete time-points of 2 weeks, 6 months, and
12 months following completion of reconstruction, tak-
ing into account time effect and time-group interaction
as shown on Table 1.
Short and long-term complication rates will be docu-
mented and collected prospectively on intraoperative
and postoperative assessment forms. Short-term compli-
cations are those that occur intraoperatively or within
the first 2 months of surgery. Surgical outcomes and
complications will be compared between the two proce-
dures as outlined on Table 2.
Long-term aesthetic result will be evaluated by a panel
of three independent blinded observers using the three-
point, five-item breast aesthetic score on standardized
five-view photographic documentation at 12-month follow-
up [29,30].
Cost-effectiveness analysis will be simultaneously an-
alyzed by collecting person-level cost and effect data.
The cost data will come from hospital cost accounting
systems and patient reports. The patient outcome data
will be collected by the BREAST-Q and the frequently
used generic EQ-5D (EuroQol Group, Rotterdam, The
Netherlands) utility measure. The primary measure of
effectiveness will be the BREAST-Q score and the sec-
ondary measure will be the quality-adjusted life year
(QALY) as measured by the EQ-5D.
Data collection
Adherence to the protocol can be enhanced when post-
operative outcomes are obtained during routine patient
follow-up with their plastic surgeons. Thus, the primary
and secondary patient-reported outcome measures will
Table 1 Timetable of interventions and outcome measurements
Baseline Week 2 Week 3 Week 4 Week 5 2 6 12





x x x x x
Group B visits
to clinic
x Expansion Expansion Expansion Expansion Expander
exchange
x x x
BREAST-Q x x x x
EQ-5D x x x
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visits by the study coordinator. In addition, the investi-
gating surgeons will complete the assessment of short-
and long-term complications and surgical outcomes at
each postoperative follow-up visit using standardized
data collection forms (Table 2). For the long-term as-
sessment, photographs will be taken by the study coord-
inator or the surgeon at the 12-month follow-up visit.
The schedule of data collection during follow-up is
shown in Table 1.
Data analysis plan
Given the stratified design, incorporating study site, sta-
tus of breast cancer, and a continuous primary outcome,
differences in the two treatments will be tested using an
analysis of variance model. Baseline BREAST-Q mea-
surements and other potentially confounding variables
(BMI, age, presence of chemotherapy or hormonal ther-
apy) that have been not balanced by randomization will
be adjusted for in the model. For secondary analyses, we
will also investigate the possibly variable effects of the
treatment group differences across multiple time-points,
namely 2 weeks, 6 months, and 12 months postopera-
tively. A linear mixed regression model will be used
where correlation between the three time-points within
a patient are appropriately accounted for in the statis-
tical inferences drawn. Potentially confounding variables
will be adjusted for in the model fit. In particular, we will
test the interaction between treatment and time. The oc-
currence of short- as well as long-term complications
will be compared between the surgical intervention
groups using Fisher’s exact test. Although confounding
is not expected due to randomization of patients to
intervention groups, any confounding factors will be ad-
justed using multivariable logistic regression models.
The logistic regression will also provide knowledge of
the relationships and strengths among the variables. The
median breast aesthetic score (I to V) for each group
will be compared using the Mann–Whitney U test
at 12-month follow-up. All analyses will follow theintention-to-treat principle. Analyses will be run primar-
ily using SAS version 9.2. The competing risk analyses
will be run using the cmprsk package in R version
2.11.1 (Institute for Statistics and Mathematics, Vienna
University of Economics and Business, Vienna, Austria).
Sample size
The primary endpoint evaluated will be the average
change in patient-reported satisfaction and QOL sum-
mary score measured using the validated BREAST-Q
from baseline compared to 12 months following recon-
struction between the two techniques. We consider clin-
ically relevant change in the QOL as a difference that
exceeds half a standard deviation of the baseline value.
We wish to detect a minimally clinically important
difference of 10 as statistically significant at the 0.05
level (two-sided), with a power equal to 0.85. Assuming
a standard deviation of 20 (through field testing of
BREAST-Q) and one interim analysis using an O’Brien-
Fleming spending function stopping boundary, a total of
73 evaluable patients per treatment group is needed.
The sample size calculation was run using PASS 2008
(NCSS, Kaysville, UT, USA). Our sample size calculation
takes into account stratification, which increases our
power to detect differences in the primary outcome be-
tween the two groups, and since our primary aim is not
to conduct formal hypothesis testing on the effects of
stratification on the outcome, the sample size calculation
reflects a conservative estimate [37]. Assuming a 1:1 al-
location ratio, 146 patients in total are required. If we
further assume a 10% loss to follow-up, we would need
to accrue 146/(1 – 0.1) = 162 patients. If the result of the
interim analysis P value is less than 0.003 then we would
consider stopping the study early. The specific boundar-
ies of the stopping rule adjust for multiple looks at the
data, while ensuring an overall type I error of 0.05. The
interim analysis will be conducted by the Data and
Safety Monitoring Board (DSMB) at the Clinical Trials
Support Unit at Princess Margaret Hospital, Toronto,
ON, Canada. One interim review by the DSMB will be
Table 2 Intraoperative, early and late postoperative surgical outcomes, and complication data collection
Intraoperative
Common intraoperative outcomes
Admission status (admitted/not admitted)
Need for completion axillary lymph node dissection (yes/no)
Mastectomy flap deemed to have significant ischemia (yes/no)
Significant mastectomy flap thickness asymmetry between two sides (yes/no)
Mastectomy weight (right breast (g)/left breast (g))
Mastectomy flap thickness (significant dermal exposure/patches of dermis exposed/thin flap without dermis exposed/normal)
Skin incision (horizontal ellipse/vertical ellipse/oblique ellipse/nipple-sparing with inframammary fold incision/nipple-sparing with lateral extension)
Sentinel lymph node biopsy (yes/no, left- and right-side)
Number of drains
Tension with skin closure (present/absent)
First stage of the two-stage Direct to implant with ADM
TE style Excess skin excision precluding one-stage implant reconstruction (yes/no)
Initial fill volume (cc) Size of ADM (cm2)
Implant style
Implant volume (g)
Implant surface and shape (round/anatomic or textured/smooth)
If TE inserted in the place of an implant: reason (implants too large/too
small/flap necrosis suspected)
Second stage surgery (exchange to implant)




Implant size and style
Implant surface and shape (round/anatomic or textured/smooth)
Within first 2 months of surgery
Common outcomes
Signs of seroma (yes/no, if yes, amount of fluid drained (cc))
Mastectomy flap viability (100%, 95 to 100%, 80 to 95%, 60 to 80%, <60%)
Need for debridement of necrosis (yes/no, if yes, debrided (cm2))
Signs of infection (yes/no, if yes, name and dosage of antibiotics prescribed)
Signs of incisional dehiscence (yes/no)
Other complications/additional comments
Number of days until drains removed
Two-stage One-stage with ADM
Need for deflation of TE (yes/no) Signs of implant malposition
(yes/no)
Signs of TE malposition (yes/no) Signs of implant exposure (yes/no)
Signs of TE exposure (yes/no) Signs of ADM exposure (yes/no)
Expansion each visit (cc)
Long-term complications common to both procedures
Signs of implant malposition (yes/no)
Signs of implant exposure (yes/no)
Signs of implant rippling (yes/no, if yes, superior/medial)
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Table 2 Intraoperative, early and late postoperative surgical outcomes, and complication data collection (Continued)
Symmetry (overall) (poor/fair/good/outstanding/excellent)
Symmetry of inframammary fold (poor/fair/good/outstanding/excellent)
Hypertrophic or keloid scar present (yes/no, assessed for each breast)
Aesthetics (poor/fair/good/outstanding/excellent, assessed for each breast)
Capsular contracture (none/II barely visible, palpable/III visible, palpable/IV severe, painful, assessed for each breast)
ADM, acellular dermal matrix; TE, tissue expander.
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1-year follow-up and are evaluable using the O’Brien-
Fleming spending function stopping boundary.
Discussion
Since the feasibility of using ADM in both one-stage
and two-stage prosthetic breast reconstruction was
first established in the literature with several case
series, ADM has ‘exploded into the marketplace and
has been integrated into the practices of many plastic
surgeons who perform prosthetic breast reconstruc-
tion’ [20-22,38-43]. In a 2010 survey of US plastic sur-
geons, over half reported frequent use of ADM as an
adjunct to implant breast reconstruction [44]. When
used as an inferolateral hammock, ADM is considered
to enhance the breast aesthetic by better defining the
IMF, allowing more lower pole fullness and reducing
the severity of capsular contraction [20].
Despite the widespread adoption of ADMs in the set-
ting of implant reconstruction, not all evidence on ADM
has been favorable. This may reflect the early learning
curve in patient selection and technique with the use of
a new surgical method, or it may be real. A recent retro-
spective review of 337 two-stage TE/I reconstructions
with and without ADM found no significant difference
between the two groups in terms of capsular contracture
and mechanical shift in the multivariate analysis [42].
Since using ADM allows for significantly higher initial
TE fill volume [40], some authors consider that the most
important application of ADM is in the setting of one-
stage direct to implant reconstruction or inadequate
local muscle coverage of the implant [20-22,38,39,41].
However, in the only RCT that examined the use of
ADM in a two-stage TE/I reconstruction, the authors
found no difference in postoperative pain or the rate of
expansion between TE/I alone compared to TE/I using
ADM as an inferolateral hammock.
Despite the mixed evidence on ADM, there is strong
interest in using ADM in implant breast reconstruction
particularly in the setting of one-stage direct to implant
reconstruction where it was previously not possible with
the use of implants alone, and always required an inter-
mediate stage with a temporary partially-inflated breast
expander. This unique advantage has led many patients
and surgeons alike to believe that one-stage ADM-assisted implant reconstruction should be the procedure
of choice, and should be offered to patients as the first-
line treatment. Although we acknowledge and share the
sentiments on the advantages of ADM-assisted reconstruc-
tion, given its cost and higher risk of infection and seroma,
we maintain our firm position that this technique should
be scientifically evaluated in terms of patient selection,
surgical technique, complications, aesthetic outcomes, cost-
effectiveness, and most importantly patient-reported satis-
faction and QOL outcomes before it is put forth as the new
gold standard in implant-based breast reconstruction. The
difficulty of undertaking such an evaluation, however, exists
on many levels and can be succinctly summarized in
Buxton’s law: ‘It is always too early [for rigorous evaluation]
until, unfortunately, it’s suddenly too late’ [45]. The use of
ADM-assisted one-stage direct to implant reconstruction
may become another example of the ad hoc nature in
which a new surgical intervention is introduced into prac-
tice without first undergoing a rigorous evaluation before-
hand. Therefore, the MCCAT study has at present a
singular and critical opportunity to use level I evidence to
evaluate the efficacy of converting a traditional two-stage
TE/I method to a single stage procedure with the use of
ADM on patient-reported outcomes, complications, aes-
thetic results, and cost-effectiveness.Risks and benefits
Most of the risks in this study are common minor and
major surgical complications shared by both the one-
and two-stage implant breast reconstruction procedures
(Table 3). The risk that is unique to the ADM group in-
cludes the rare possibility of pathogen or disease trans-
mission from the processed human cadaveric donor
tissue. However, there have not been any case reports of
disease or infection transmitted by human ADM to date.
A final important risk is that in about 5% of the cases
where subjects are randomized to the ADM-assisted
one-stage arm, if the mastectomy flap thickness is found
to be too thin or avascular to provide healthy cover for
the ADM/implant construct, then the technique will be
converted to the traditional TE insertion technique. The
most important benefit that can be derived from this
study is the possibility of having a breast mound com-
pletely reconstructed in a single stage at the same time
Table 3 Surgical risks to participants
Surgical complications common to both surgical methods
Major complications Minor complications
Implant or TE infection requiring removal of the prosthesis
(3%, 80% reversible)
Implant or TE infection requiring only antibiotics
(3% not severe, 100% reversible)
Mastectomy skin flap problems resulting in removal of
implant or TE (2%, 80% reversible)
Mastectomy skin flap problems requiring only conservative treatment
and minor debridement in clinic (2% not severe, 100% reversible)
Implant movement requiring additional surgery (3%, 80% reversible) Visible implant rippling, shape deformity, or poor alignment
not requiring correctional surgery (10 to 20%)
Implant rippling, shape deformity, or poor alignment requiring
surgery to correct it (10% not reversible)
Seroma or hematoma (1 to 2% not severe, 100% reversible)
Long-term capsular contracture formation (25% develop
grades III to IV in 10 years, not reversible)
Possible complications present in the two-stage TE/I method Possible complications present in the ADM one-stage method
All need a second surgery for TE exchanged to implant under
another general anesthetic
Hypothetical risk of pathogen or disease transmission from the
processed human cadaveric donor tissue
All need at least one postoperative TE inflation, on average three
inflations that are performed either weekly or biweekly
One-stage method may not be possible for patients who wish to
have larger breast sizes postoperative than they had preoperative
All need to wait approximately 3 (±1) months following completion
of the TE expansion process prior to the second surgery
Need for two drains rather than one drain per breast
May be discomfort associated with TE inflation Some reports of increased seroma formation with the use of ADM
Saline leak from the TE may occur and can result in an additional surgery May be more pain postoperatively with suturing of the ADM
down to the chest wall along the inframammary fold
TE may be malpositioned or migrate postoperatively requiring
revision surgery prior to TE exchange
There may be more asymmetry between the two sides since
there is only surgery to reconstruct the breast mound (versus
two opportunities for symmetry correction in the two-stage)
May be additional complications resulting from two surgeries Less control with the patients selecting the volume of their
reconstructed breasts compared to the two-stage TE/I group
May be higher risk of hematoma formation from the need to
elevate pectoralis major, serratus major, and rectus fascia
May be more surgical pain associated from the need to elevate
pectoralis major, serratus major, and rectus fascia
All need a second surgery for TE exchanged to implant under
another general anesthetic
ADM, acellular dermal matrix; TE, tissue expander; TE/I, tissue expander/implant.
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without the use of ADM.
Ethical considerations
Clinical equipoise exists in this trial since no prior stud-
ies have compared patient-reported outcomes or risks/
complications following the two types of implant-based
breast reconstruction. Institutional Research Ethics Board
(REB) approval has been obtained for all the study sites
along with the data share agreements with the primary
study site. Research staff will also ensure that protocol
subjects receive Notice of Privacy Practices. Any serious
adverse events will be reported to the REB as soon as pos-
sible but no later than 5 calendar days.
Limitations and strengths
Blinding of participants and surgeons is impossible given
the intervention. This may bias the primary outcomesince QOL may seem a subjective endpoint; however,
the BREAST-Q is a validated, reliable assessment of
QOL that should provide a robust measure of satisfac-
tion. The assessment of the overall aesthetic outcome,
however, uses independent blinded judges and therefore
reduces the bias when evaluating this secondary out-
come. Secondly, although it would have been preferable
to stratify important baseline covariates such as breast
cancer stage (prophylactic versus in situ versus invasive
breast cancer), it would have added too many strata rela-
tive to our sample size. In addition, although stratifica-
tion based on whether the patient will require adjuvant
chemo- or hormonal therapy would have been desirable,
this information is not generally available at the time of
randomization, nor is it in ‘real life’, as it only becomes
known with the final pathologic evaluation of the mast-
ectomy and sentinel lymph node. Therefore, our ap-
proach will be to adjust these confounders in the
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http://www.trialsjournal.com/content/14/1/356analysis. The 1-year duration for follow-up does not take
into account revision surgeries that occur later than
1 year, therefore interpretation of the results should also
be limited to this duration. The greatest strength of this
study is the use of the randomized controlled design as
the most stringent study design to elucidate a true
cause-effect relationship between our intervention (one-
stage ADM reconstruction) and effect (improved patient
outcomes) by balancing both known and unknown vari-
ables in a relatively mixed mastectomy population.
Trial status
Trial inception
The MCCAT study was initially designed as a multicentre
trial that involved only two centres in Toronto, ON,
Canada, and began enrollment in October 2009. After
1.5 years, the third centre, Vancouver General Hospital, BC,
Canada, was recruited in April 2011, followed by the fourth
centre in Calgary, AB, Canada, in January 2013 to increase
recruitment and generalizability of results.
Eligible patients
At the date of manuscript preparation, a total of 149 pa-
tients have been deemed eligible and 121 patients have
been enrolled into the trial.
Operated patients
In addition, 106 patients have undergone their allocated
intervention (mastectomy surgery with either TE inser-
tion or one-stage direct to implant using ADM; seven
patients are awaiting surgery, four patients withdrew
from the study, one patient was deemed ineligible, three
patients did not receive allocated intervention). To date,
63 patients have completed the trial and are evaluable
for the primary outcome.
Protocol amendment
The protocol was amended in October 2011 to include
an additional time-point for completing the BREAST-Q
instrument in the control group at 6 months following
mastectomy and insertion of TE after the first stage. The
research team considered that although patients were
still in the mid-process of reconstruction during expan-
sion, answering the BREAST-Q would provide a better
understanding of the impact of reconstruction on their
interim QOL.
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